Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CLYM
HoldClimb Bio, Inc. · Healthcare · United States · $837M · Avg Vol: $17M/d
COMPANY DESCRIPTION
Climb Bio, Inc. is a preclinical-stage biotechnology company focused on discovering and developing innovative therapies for unmet medical needs, likely leveraging specific scientific platforms or therapeutic modalities. The company aims to establish a competitive edge through proprietary scientific platforms or novel drug candidates that target specific disease mechanisms. Climb Bio is an emerging biotech firm dedicated to groundbreaking research and development, seeking to create transformative treatments within its specialized therapeutic area.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | 0.5M | — |
| EPS | -0.80 | -0.63 | -1.53 | -0.88 | — | -0.82 | -0.78 | -1.05 | — |
| Shares | 57.3M | 57.3M | 67.3M | 47.8M | -16.6% | 57.4M | — | — | — |
| Debt | 0.5M | 0.3M | 0.5M | 0.5M | 4.1% | 1.3M | — | — | — |
| Equity | 128.7M | 107.6M | 211.9M | 160.5M | 7.6% | — | — | — | — |
| Op CF | -37.4M | -20.6M | -15.6M | -54.4M | — | -52.7M | — | — | — |
| Inv CF | 34.4M | 69.0M | -121.1M | 2.8M | — | — | — | — | — |
| Fin CF | 0 | 0.8M | 130.7M | -21.0K | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CLYM are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CLYM | Climb Bio, Inc.(you) | $837M | 39 | Hold |
| SLDB | Solid Biosciences Inc. | $1.0B | 38 | Hold |
| ASMB | Assembly Biosciences, Inc. | $694M | 42 | Hold |
| GYRE | Gyre Therapeutics, Inc. | $699M | 35 | Hold |
| TECX | Tectonic Therapeutic, Inc. | $696M | 35 | Hold |
| NGNE | Neurogene Inc. | $732M | 34 | Sell |
| DSGN | Design Therapeutics, Inc. | $946M | 33 | Sell |
| OVID | Ovid Therapeutics Inc. | $547M | 39 | Hold |
| FTH | Faeth Therapeutics, Inc. | $874M | 31 | Sell |
| IMMX | Immix Biopharma, Inc. | $992M | 34 | Sell |
Peer medians: ROE -24.4% · P/E 31.0x · Gross margin 58.8%